The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis

Background and Aims: Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this study explored the therapeutic effects of a novel...

Full description

Bibliographic Details
Main Authors: Sandra Torres, Maximilian J Brol, Fernando Magdaleno, Robert Schierwagen, Frank E. Uschner, Sabine Klein, Cristina Ortiz, Olaf Tyc, Nadine Bachtler, James Stunden, Damien Bertheloot, Ana Kitanovic, Brian Sanchez, Jacob Schrum, William R. Roush, Luigi Franchi, Kate Byth, Eicke Latz, Jonel Trebicka
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Molecular Biosciences
Subjects:
inflammasome
liver fibrosis
steatosis
NASH
caspase-1
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.715765/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.715765/full

Similar Items